CANTREAT

CANTREAT® is currently offering investors the opportunity to purchase shares. The funds raised will be used to finance further research. A market launch is considered realistic by experts in 2-4 years... CANTREAT® is a groundbreaking new technology that will make it possible in the future to perform chemotherapies with maximum reduction of the numerous, often serious side effects... Build an impressive website with the best-rated top-seller WordPress theme

Also known as: Cantreat AG

VAT numbers: CHE-404.109.690

Primary location: Wollerau Switzerland